Medicenna Announces Upcoming Presentation at the AACR Annual Meeting
TORONTO and HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 – 19, 2023.
The full text of the published abstract can be found on the AACR Annual Meeting website. Details on the corresponding poster are shown below.
Poster Title: Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine for Targeted Delivery of Immunotherapies to the Tumor Microenvironment
Session Category: Immunology
Session Title: Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies
Session Date and Time: April 16, 2023; 1:30 pm – 5:00 pm ET
Abstract Number: 708
The poster will describe preclinical studies characterizing a long-acting version of MDNA132 and BiSKITs™, (Bifunctional SuperKine ImmunoTherapies) comprising MDNA132 fused to an IL-2 super-agonist or anti-PD1 antibody. MDNA132 is an IL-13 Superkine designed to enable targeted delivery of immunotherapies to the tumor microenvironment. MDNA132 exhibits high affinity and selectivity for the IL13Ra2, which is highly overexpressed in various tumors such as pancreatic, prostate, bladder, colorectal, breast and lung cancer but minimally expressed in healthy tissues.
Following the conclusion of the AACR Meeting, a copy of the poster will be available on the “Events and Presentations” page of Medicenna’s website.
Forward Looking Statements
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
For further information about the Company please contact:
Elizabeth Williams, Chief Financial Officer, 416-648-5555, [email protected]
For more investor information, please contact:
Dan Ferry, Managing Director, LifeSci Advisors, 617-430-7576, [email protected]